This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.
Drug Candidates
22 candidates mapped to SDH-deficient disease pathways
Zejula
PARP inhibitor (PARP1/2)
Balversa
Pan-FGFR inhibitor (FGFR1/2/3/4), FDA-approved
OTX015, MK-8628
BET bromodomain inhibitor (pan-BRD2/3/4)
Keytruda
Anti-PD-1 monoclonal antibody (checkpoint inhibitor)
Truqap
Pan-AKT inhibitor (allosteric PH-domain binding; AKT1/2/3)
Farydak
Pan-HDAC inhibitor
Ibrance
CDK4/6 inhibitor
AZD7648
DNA-PKcs inhibitor (DNA-dependent protein kinase catalytic subunit inhibitor)
Idhifa
IDH2 inhibitor
DUP-785, NSC 368390
DHODH inhibitor (dihydroorotate dehydrogenase inhibitor)
LY2606368
CHK1/CHK2 kinase inhibitor
M3814
DNA-PK (DNA-PKcs/PRKDC) inhibitor
STA-9090
HSP90 inhibitor (non-ansamycin resorcinol-based)
ENPP1 inhibitor
Rytelo
Telomerase inhibitor (competitive TERT template antagonist)
MK-1454
Cyclic dinucleotide STING agonist (intratumoral)
Iwilfin, Ornidyl
ODC1 inhibitor (ornithine decarboxylase inhibitor / polyamine synthesis inhibitor)
Pyruvate dehydrogenase kinase inhibitor
INCB024360
IDO1 inhibitor (indoleamine 2,3-dioxygenase 1 inhibitor)
Aubagio
DHODH inhibitor (active metabolite of leflunomide; FDA-approved)
AMD3100, Mozobil
CXCR4 chemokine receptor antagonist
TET enzyme cofactor / α-KG-dependent dioxygenase activator